Clinical trials: Diabetes Type I
Type 1 Diabetes Mellitus
Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus
This is a multicenter, randomized, partial-blinded, five-arm, placebo-controlled study of human plasma-derived alpha1-proteinase inhibitor (alpha1-PI) in children (ages 6-11 years old) and teens/adults (ages 12-35 years old) with…
- Trial name
- NCT02093221
- Testing
- 180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI
- Where
- 36 sites in United States
- Volunteers
- 76 people
- Sponsor
- Grifols Therapeutics LLC
Diabetes Mellitus, Type 1
Safety of ENC-201-CED ENCRT
The purpose of the study is to evaluate the safety and tolerability of ENC-201-CED in a subcutaneous space in patients with Type I diabetes.
- Trial name
- NCT06408311
- Testing
- ENC-201-CED hPI
- Where
- 2 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Encellin
Type 1 Diabetes, Type 2 Diabetes
Using SCOUT Noninvasive AGE Measurements to Forecast Diabetes Complications
The trial is designed as a feasibility study to determine the correlation of noninvasive measurements of AGE with the SCOUT device to diabetes complications.
- Trial name
- MARC (NCT01415115)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- VeraLight, Inc.
Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
A 13-week multi-center single-arm trial, preceded by a 2-week standard therapy phase, will be conducted to assess the safety of MODI, an insulin titration algorithm, in adults with type 1 diabetes (T1D) who use multiple daily…
- Trial name
- MODIUS (NCT07599982)
- Testing
- MODI Algorithm
- Where
- 6 sites in United States
- Volunteers
- 102 people
- Sponsor
- DreaMed Diabetes
Solid Tumor, Lymphoma
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in…
- Trial name
- NCT03013491
- Testing
- CX-072, ipilimumab, vemurafenib
- Where
- 31 sites in United States, Netherlands and 4 more
- Volunteers
- 196 people
- Sponsor
- CytomX Therapeutics
Type 1 Diabetes
A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes
Primary Objective: To compare exposure and activity of SAR342434 to US-approved and EU-approved Humalog®. Secondary Objective: To assess the safety and tolerability of SAR342434.
- Trial name
- NCT02273258
- Testing
- SAR342434, Insulin Lispro
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus
To evaluate non-inferiority in the efficacy of HMR1964 as compared with Insulin lispro in terms of the change in HbA1C from baseline to endpoint. To compare the safety of HMR1964 with insulin lispro.
- Trial name
- NCT00290979
- Testing
- insulin glulisine
- Where
- Japan
- Volunteers
- 250 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1, Hypoglycemia
T1 Diabetes Hypoglycemia Prevention Pilot
A single center pilot study assessing the Vigilant Diabetes Management System for the prevention of recurrent mild to moderate hypoglycemia in type I diabetes patients.
- Trial name
- NCT02682940
- Testing
- Vigilant Diabetes Management Application
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- InSpark Technologies, Inc.
Diabetes Mellitus
Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure
The purpose of this study is to compare the safety of Pioglitazone, once daily (QD), to Glyburide in Type 2 Diabetes Subjects with Mild to Moderate Congestive Heart Failure
- Trial name
- NCT00521820
- Testing
- Pioglitazone, Glyburide
- Volunteers
- 518 people
- Sponsor
- Takeda
Diabetes, Diabetes Mellitus, Type 1
An Observational Study to Compare the Safety and Effectiveness of NovoMix® 30 and Levemir™ for the Treatment of Diabetes
This study is conducted in Asia. The aim of this observational study is to compare the clinical safety profile and effectiveness of NovoMix® 30 and Levemir™ for the treatment of diabetes in the Philippines.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- SAFE (NCT00789711)
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- Philippines
- Volunteers
- 3,131 people
- Sponsor
- Novo Nordisk A/S
Diabetes Type 1
Impact of the Mylife CamAPS FX System With the DEXCOM G6 Sensor on T1D Patients in France
This is a non-interventional, longitudinal, prospective, multicenter, post market-registration and national study conducted in France.
- Trial name
- EPICAM-G6 (NCT07048795)
- Testing
- No Intervention: Observational Cohort
- Where
- 22 sites in France
- Volunteers
- 125 people
- Sponsor
- mylife Diabetes Care AG
Diabetes, Diabetes Mellitus, Type 1
Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction in Children and Adolescents With Type 1 Diabetes
This study is conducted in Asia, Europe and North America. The aim of this observational study is to evaluate the safety of NovoPen Echo® by collecting safety information (incidence of technical complaints related to adverse…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Delivery Systems
- Trial name
- REMIND™ (NCT01180530)
- Testing
- NovoPen Echo®
- Where
- 5 sites in Canada, Finland and 2 more
- Volunteers
- 358 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes
A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes
- Trial name
- NCT07004153
- Testing
- Smart Coaching Insulin Pen
- Where
- South Korea
- Volunteers
- 152 people
- Sponsor
- G2e Co., Ltd
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
This is an open label, two-arm, randomized multi-center clinical device study in adult subjects with Type 1 diabetes (T1D) or insulin-dependent Type 2 diabetes (T2D) on a multiple daily injection (MDI) regime.
- Trial name
- NCT06704672
- Testing
- Accu-Chek SmartGuide CGM Solution, Accu-Chek SmartGuide Sensor and Blinded Apps, SMBG Device
- Where
- 20 sites in Poland, Turkey (Türkiye)
- Volunteers
- 270 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 1
Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control
Multi-Center, double blind, active comparator controlled multiple dose safety, tolerability and efficacy study
- Trial name
- NCT03096392
- Testing
- HDV insulin lispro 100 UNT/ML, Insulin Lispro 100 UNT/ML
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Diasome Pharmaceuticals
Type 1 Diabetes, Type2diabetes
Liom Non-invasive Continuous Glucose Monitor "Clinical Demo" (niCGM)
This is a single-centre, multiple cohort, open study.
- Trial name
- NCT06272136
- Testing
- Clinical Demo 2.0
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Liom Health AG
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice
This study is to investigate the effects of Fiasp®, a mealtime insulin, in patients with diabetes mellitus. The purpose of this study is to collect information about Fiasp®, which is prescribed to the participants by their…
- Trial name
- NCT03987802
- Testing
- Faster-acting insulin aspart
- Where
- 36 sites in India
- Volunteers
- 42 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
This trial is conducted in Europe, Oceania, and the United States of America (USA). The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin detemir (IDet) plus insulin aspart…
- Trial name
- BOOST™ (NCT00978627)
- Testing
- insulin degludec/insulin aspart, insulin detemir, insulin aspart
- Where
- 81 sites in United States, Australia and 8 more
- Volunteers
- 548 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689
This trial is conducted in Europe. The aim of this research is to assess the safety of continuous treatment with insulin detemir following participation in trial NN304-1689 (NCT00435019) on antibody development.
- Trial name
- NCT00623194
- Testing
- insulin detemir, insulin aspart
- Where
- 32 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 146 people
- Sponsor
- Novo Nordisk A/S